Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine the role of nitric oxide (NO) in asthma. We determine the effect of promoter polymorphisms in the gene for the NO producing enzyme, nitric oxide synthase (NOS2), on exhaled NO in healthy African Americans and Caucasians. We compare exhaled NO levels between African Americans and Caucasians. Information on race or ethnicity, serum samples, blood pressure, exhaled breath condensate and health questionnaires will be collected.
| Condition |
|---|
|
Healthy Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1 |
Serum samples, DNA, Exhaled Breah Condensate
| Estimated Enrollment: | 1600 |
| Study Start Date: | May 2003 |
| Estimated Study Completion Date: | December 2008 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
African American
|
|
2
Caucasian
|
Detailed Description:
The purpose of the study is to determine the role of nitric oxide (NO) in asthma. We determine the effect of promoter polymorphisms in the gene for the NO producing enzyme, nitric oxide synthase (NOS2), on exhaled NO in healthy African Americans and Caucasians. We compare exhaled NO levels between African Americans and Caucasians. Information on race or ethnicity, serum samples, blood pressure, exhaled breath condensate and health questionnaires will be collected.
Three single nucleotide polymorphisms (SNPs) have been identified in Africans that are associated with increases in systemic NO production. These studies determine whether the NOS2 promoter SNPs are associated with differences in basal exhaled NO levels. The study of exhaled NO levels in individuals with asthma is confounded by the presence of cell types besides bronchial epithelium that produce NO, by differences in the severity of asthma and by the use of medications such as corticosteroids which alter exhaled NO levels.
Therefore, in this study exhaled NO levels in asymptomatic healthy African Americans and Caucasians are measured. The initial analysis of exhaled NO levels indicate that a subset of African American samples contained lower levels of NO than previous measurements of exhaled NO levels in Caucasians. Because differences in exhaled NO levels may influence bronchodilation and other airway responses, as part of this study, the exhaled NO levels of the African American subjects are compared to the results of sample collections from Caucasian samples.
In addition to measures of exhaled NO levels, information on race or ethnicity and DNA samples are collected to characterize samples collected from African American and Caucasian subjects. Serum samples, measures of blood pressure and exhaled breath condensate samples are collected from African Americans and Caucasians to control for confounding variables. Repeated measures of exhaled NO levels are collected to control for fluctuations in exhaled NO levels related to upper respiratory infections.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Community sample
Inclusion Criteria:
- Willing/able to give informed consent
- self declared non-atopic, non-asthmatic
- never cigarette smoker,
- no significant occupational exposure to respiratory irritants or toxins,
- no chronic illness
- no chronic use of medications (excluding contraceptive medication),
- no historical unstable cardiac or severe lung disease,
- within study age parameters of 18 - 40
Exclusion Criteria:
- occupational exposure to hay or grain
- smoked 20 or more packs of cigarettes in a lifetime.
- prior allergen immunotherapy
- Allergy and or asthma
- Students or employees under direct supervision by protocol investigators are ineligible
- Nursing mothers
- pregnancy
- Other investigational medication within the last 30 days
- Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Contacts and Locations| Contact: Catherine M Foss, B.S. | (919)668-3599 | foss0005@mc.duke.edu |
| Contact: Marc C Levesque, M.D., PhD | (919) 613-7931 | marc.levesque@duke.edu |
| United States, North Carolina | |
| Duke University Medical Center | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Contact: Catherine M Foss, B.S. 919-668-3599 foss0005@mc.duke.edu | |
| Contact: John S Sundy, M.D., PhD. (919) 668-2169 john.sundy@duke.edu | |
| Sub-Investigator: John S Sundy, M.D., PhD | |
| Principal Investigator: | Marc C Levesque, M.D., PhD | Duke University |
More Information
Publications:
| Responsible Party: | Marc C. Levesque, NIEHS |
| ClinicalTrials.gov Identifier: | NCT00671229 History of Changes |
| Other Study ID Numbers: | 12496-CP-006A, Pro00005046 |
| Study First Received: | May 2, 2008 |
| Last Updated: | May 2, 2008 |
| Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by National Institute of Environmental Health Sciences (NIEHS):
|
Healthy Asthma Nitric Oxide |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Nitric Oxide Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Cardiovascular Agents Protective Agents |
ClinicalTrials.gov processed this record on June 18, 2013